Citadel Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $679K | Buy |
+8,571
| New | +$693K | ﹤0.01% | 8556 |
|
|
2025
Q4 | – | Sell |
-2,953
| Closed | -$206K | – | 13702 |
|
|
2025
Q3 | $206K | Buy |
+2,953
| New | +$200K | ﹤0.01% | 11196 |
|
|
2025
Q1 | – | Sell |
-8,551
| Closed | -$569K | – | 15297 |
|
|
2024
Q4 | $569K | Buy |
+8,551
| New | +$590K | ﹤0.01% | 8277 |
|
|
2024
Q2 | – | Sell |
-4,111
| Closed | -$266K | – | 15085 |
|
|
2024
Q1 | $266K | Buy |
+4,111
| New | +$268K | ﹤0.01% | 9731 |
|
|
2023
Q4 | – | Sell |
-8,949
| Closed | -$510K | – | 14975 |
|
|
2023
Q3 | $510K | Buy |
+8,949
| New | +$546K | ﹤0.01% | 8031 |
|
|
2023
Q2 | – | Sell |
-6,659
| Closed | -$418K | – | 14990 |
|
|
2023
Q1 | $418K | Buy |
+6,659
| New | +$429K | ﹤0.01% | 8672 |
|
|
2022
Q3 | – | Sell |
-10,843
| Closed | -$626K | – | 13337 |
|
|
2022
Q2 | $626K | Buy |
10,843
+6,564
| +153% | +$378K | ﹤0.01% | 8145 |
|
|
2022
Q1 | $265K | Buy |
+4,279
| New | +$261K | ﹤0.01% | 10878 |
|
|
2021
Q4 | – | Sell |
-3,082
| Closed | -$231K | – | 14483 |
|
|
2021
Q3 | $231K | Sell |
3,082
-850
| -22% | -$64.8K | ﹤0.01% | 11662 |
|
|
2021
Q2 | $304K | Sell |
3,932
-3,964
| -50% | -$295K | ﹤0.01% | 11229 |
|
|
2021
Q1 | $583K | Buy |
7,896
+3,166
| +67% | +$239K | ﹤0.01% | 9348 |
|
|
2020
Q4 | $332K | Sell |
4,730
-26,767
| -85% | -$1.69M | ﹤0.01% | 8891 |
|
|
2020
Q3 | $1.78M | Buy |
+31,497
| New | +$1.85M | ﹤0.01% | 4926 |
|
|
2020
Q2 | – | Sell |
-38,062
| Closed | -$1.77M | – | 10311 |
|
|
2020
Q1 | $1.77M | Sell |
38,062
-5,771
| -13% | -$301K | ﹤0.01% | 4341 |
|
|
2019
Q4 | $2.45M | Sell |
43,833
-6,505
| -13% | -$339K | ﹤0.01% | 4088 |
|
|
2019
Q3 | $2.38M | Buy |
+50,338
| New | +$2.58M | ﹤0.01% | 4205 |
|
|
2019
Q2 | – | Sell |
-34,238
| Closed | -$1.89M | – | 9681 |
|
|
2019
Q1 | $1.89M | Buy |
34,238
+29,288
| +592% | +$1.55M | ﹤0.01% | 4560 |
|
|
2018
Q4 | $233K | Buy |
+4,950
| New | +$254K | ﹤0.01% | 7649 |
|
|
2018
Q3 | – | Sell |
-13,348
| Closed | -$730K | – | 9564 |
|
|
2018
Q2 | $730K | Buy |
13,348
+8,832
| +196% | +$449K | ﹤0.01% | 5754 |
|
|
2018
Q1 | $222K | Sell |
4,516
-3,969
| -47% | -$202K | ﹤0.01% | 7193 |
|
|
2017
Q4 | $400K | Buy |
+8,485
| New | +$398K | ﹤0.01% | 5996 |
|
|
2017
Q2 | – | Sell |
-32,667
| Closed | -$1.38M | – | 7898 |
|
|
2017
Q1 | $1.38M | Buy |
32,667
+1,792
| +6% | +$75.1K | ﹤0.01% | 3538 |
|
|
2016
Q4 | $1.2M | Sell |
30,875
-20,004
| -39% | -$808K | ﹤0.01% | 3619 |
|
|
2016
Q3 | $2.13M | Buy |
50,879
+40,670
| +398% | +$1.67M | ﹤0.01% | 2897 |
|
|
2016
Q2 | $378K | Sell |
10,209
-10,788
| -51% | -$423K | ﹤0.01% | 4882 |
|
|
2016
Q1 | $804K | Sell |
20,997
-15,009
| -42% | -$583K | ﹤0.01% | 3744 |
|
|
2015
Q4 | $1.82M | Buy |
36,006
+9,133
| +34% | +$451K | ﹤0.01% | 2835 |
|
|
2015
Q3 | $1.23M | Buy |
+26,873
| New | +$1.5M | ﹤0.01% | 3551 |
|
|
2015
Q2 | – | Sell |
-29,803
| Closed | -$1.64M | – | 8975 |
|
|
2015
Q1 | $1.64M | Buy |
+29,803
| New | +$1.61M | ﹤0.01% | 3324 |
|
|
2014
Q2 | – | Sell |
-21,039
| Closed | -$876K | – | 8210 |
|
|
2014
Q1 | $876K | Buy |
+21,039
| New | +$900K | ﹤0.01% | 3597 |
|
Other funds holding PBE
UCFA
GKWIM
YIA
Citadel Advisors's PBE Position: Q1 2026 in Review
Citadel Advisors opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q1 2026: 8,571 shares worth $679K. The stake represents ﹤0.01% of the portfolio and ranks #8556 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PBE as recently as Q3 2025.
Citadel Advisors first reported a position in PBE in Q1 2014 and has held it in 30 quarters since. The position peaked at $2.45M in Q4 2019. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.
- Citadel Advisors held 8,571 shares of Invesco Biotechnology & Genome ETF worth $679K as of Q1 2026.
- Invesco Biotechnology & Genome ETF was a new Citadel Advisors position in Q1 2026.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8556 holding.
- Citadel Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and has held it in 30 quarters since.
- Citadel Advisors's Invesco Biotechnology & Genome ETF position peaked at $2.45M in Q4 2019.
- 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.